1. Home
  2. XBIT vs PLRX Comparison

XBIT vs PLRX Comparison

Compare XBIT & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.35

Market Cap

69.8M

Sector

Health Care

ML Signal

HOLD

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

HOLD

Current Price

$1.11

Market Cap

65.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
PLRX
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.8M
65.6M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
XBIT
PLRX
Price
$2.35
$1.11
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
$2.67
AVG Volume (30 Days)
32.8K
391.9K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.97
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$1.02
52 Week High
$3.61
$1.95

Technical Indicators

Market Signals
Indicator
XBIT
PLRX
Relative Strength Index (RSI) 54.27 51.02
Support Level $2.27 N/A
Resistance Level $2.45 $1.27
Average True Range (ATR) 0.06 0.03
MACD 0.01 0.01
Stochastic Oscillator 48.00 80.00

Price Performance

Historical Comparison
XBIT
PLRX

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Share on Social Networks: